BridgeBio Pharma, Inc.
BBIO
$66.54
$2.013.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 27.74% | 9.17% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.74% | 9.17% | |||
| Cost of Revenue | 23.53% | 79.66% | |||
| Gross Profit | 27.98% | 6.76% | |||
| SG&A Expenses | 14.87% | 6.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.94% | 5.34% | |||
| Operating Income | 5.81% | -2.16% | |||
| Income Before Tax | -4.44% | -2.66% | |||
| Income Tax Expenses | 92.23% | -173.57% | |||
| Earnings from Continuing Operations | -5.24% | -0.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -19.23% | 18.27% | |||
| Net Income | -5.54% | -0.46% | |||
| EBIT | 5.81% | -2.16% | |||
| EBITDA | 5.90% | -2.12% | |||
| EPS Basic | -4.61% | 0.24% | |||
| Normalized Basic EPS | -2.91% | 2.79% | |||
| EPS Diluted | -4.61% | 0.24% | |||
| Normalized Diluted EPS | -2.91% | 2.79% | |||
| Average Basic Shares Outstanding | 0.89% | 0.70% | |||
| Average Diluted Shares Outstanding | 0.89% | 0.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||